MGC Pharmaceuticals’ (ASX:MXC) results suggest further applications for CimetrA
MGC Pharmaceuticals (MXC) indicates CimetrA has a wide-ranging application as an anti-inflammatory…
Change | ||
S&P/ASX Sm. Ords. | |||
All Ordinaries | |||
S&P/ASX 100 |
CDD | CARDNO LIMITED | 32.5¢ | 195% |
CBE | COBRE LIMITED | 5.4¢ | 38.5% |
SZL | SEZZLE INC. | 53.0¢ | 35.9% |
BEX | BIKEEXCHANGE LIMITED | 2.3¢ | 25.8% |
SXG | SOUTHERN CROSS GOLD LTD | 37.0¢ | 23.7% |
TG6 | TG METALS LIMITED | 11.5¢ | 23.3% |
Date | Announcement | File | Views |
---|---|---|---|
06/07/2022 | Launch of Medical Data Collection App - ZAM | 951.45KB | 422 |
27/06/2022 | Price Sensitive PS CimetrA anti-inflammatory pre-clinical study results | 1.11MB | 5.3K |
24/06/2022 | US Market Update - CimetrA Clinical Trial Progress | 240.54KB | 600 |
16/06/2022 | Price Sensitive PS Glioblastoma pre-clinical trial results | 1.14MB | 2.1K |
06/06/2022 | Price Sensitive PS Cognicann Clinical Trial Results | 348.51KB | 3.0K |
18/05/2022 | Price Sensitive PS Response to ASX Aware Query | 1.18MB | 2.2K |
13/05/2022 | s708A(5)(e) Cleansing Notice | 232.99KB | 278 |
13/05/2022 | Application for quotation of securities - MXC | 24.97KB | 1.6K |